…
Lexeo Therapeutics, Inc., a clinical stage genetic medicine company, focuses on hereditary and acquired diseases with high unmet need in the United States. Its product pipeline comprises LX2006, an AAVrh10-based gene therapy candidate, which is in phase 1/2 clinical trial to treat friedreich ataxia cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate, which is in phase 1/2 to deliver a functional plakophilin-2 (PKP2) gene to cardiac muscle for the treatment of PKP2-ACM; and LX2021, a gene therapy candidate, which is in preclinical trial to deliver the coding sequence for the functional connexin 43, or Cx43, protein for a group of inherited cardiac muscle disorders associated with a high risk of sudden death, including arrhythmogenic cardiomyopathy (ACM) and certain forms of dilated cardiomyopathy. The company is also developing LX2022, a gene therapy candidate, which is in preclinical trial to deliver a functional TNNI3 gene to myocardial cells to treat a distinct form of hypertrophic cardiomyopathy. In addition, it is developing LX1001, LX1020, and LX1021, an AAVrh10-based gene therapy candidate, which has completed phase 1/2 clinical trial for the treatment of APOE4-associated Alzheimer's disease. The company has a license agreement with Cornell University to conduct the Phase 1/2 clinical trial of LX1001, as well as support the development of the LX1004 program; a research collaboration agreement with Cornell University to conduct preclinical research to develop the licensed technology; and third license agreement which obtained certain rights for FA cardiomyopathy, including rights to current and future clinical data from an ongoing Cornell University investigator-initiated Phase 1A trial of a gene therapy candidate. The company was founded in 2017 and is headquartered in New York, New York.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -99.96M | -98.33M | -66.39M | -59.28M | -50.62M |
| Net income | -99.96M | -98.33M | -66.39M | -59.28M | -50.62M |
| Selling general administrative | 45.46M | 31.68M | 15.38M | 12.00M | 7.17M |
| Selling and marketing expenses | - | - | 1.84M | - | - |
| Gross profit | -2.08M | -2.00M | -1.84M | 0.65M | 1.66M |
| Reconciled depreciation | 2.08M | 2.00M | 1.84M | 1.15M | 0.01M |
| Ebit | -99.75M | -98.20M | -66.19M | -59.19M | -50.62M |
| Ebitda | -97.68M | -96.19M | -64.35M | -58.04M | -50.61M |
| Depreciation and amortization | 2.08M | 2.00M | 1.84M | 1.15M | 0.01M |
| Operating income | -109.26M | -105.77M | -68.51M | -60.51M | -50.64M |
| Other operating expenses | 109.26M | 105.77M | 68.51M | 61.16M | 52.29M |
| Interest expense | 0.21M | 0.11M | 0.20M | 0.09M | 0.00M |
| Tax provision | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Interest income | 6.13M | 7.58M | 2.87M | 1.32M | 0.01M |
| Net interest income | 5.92M | 7.44M | 2.66M | 1.23M | 0.01M |
| Income tax expense | - | - | -0.00M | 0.09M | -0.00M |
| Total revenue | 0.00M | 0.00M | 0.00M | 0.65M | 1.66M |
| Total operating expenses | 109.26M | 105.77M | 68.51M | 61.16M | 52.29M |
| Cost of revenue | 2.08M | 2.00M | 1.84M | - | - |
| Total other income expense net | 9.30M | 7.43M | 2.12M | -0.00M | -0.00M |
| Net income from continuing ops | -99.96M | -98.33M | -66.39M | -59.28M | -50.62M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 268.69M | 146.94M | 139.81M | 97.08M | 136.86M |
| Other current assets | 6.62M | 4.60M | 0.00M | 0.37M | 0.70M |
| Total liab | 22.02M | 30.10M | 26.27M | 210.03M | 192.46M |
| Total stockholder equity | 246.67M | 116.84M | 113.53M | -112.95M | -55.60M |
| Other current liab | 9.28M | 13.76M | 0.17M | 8.84M | 4.34M |
| Common stock | 0.01M | 0.00M | 0.00M | 0.00M | 0.00M |
| Capital stock | 0.01M | 0.00M | 0.00M | 0.00M | 0.00M |
| Retained earnings | -380.13M | -280.17M | -181.84M | -115.45M | -56.17M |
| Cash | 63.00M | 35.01M | 121.47M | 77.33M | 135.86M |
| Total current liabilities | 16.81M | 22.85M | 17.24M | 14.35M | 7.45M |
| Current deferred revenue | - | - | 10.67M | 8.60M | 0.05M |
| Net debt | -55.11M | -25.09M | -109.83M | -63.85M | -135.86M |
| Short term debt | 2.67M | 2.67M | 2.60M | 2.83M | 4.31M |
| Short long term debt total | 7.89M | 9.92M | 11.64M | 13.48M | - |
| Other stockholder equity | 626.61M | 397.12M | 295.37M | 2.49M | 0.56M |
| Total current assets | 188.39M | 126.12M | 124.29M | 80.05M | 136.68M |
| Long term investments | 68.19M | 7.01M | - | - | - |
| Short term investments | 118.77M | 86.50M | - | - | - |
| Accounts payable | 4.86M | 6.42M | 3.79M | 2.68M | 3.06M |
| Accumulated other comprehensive income | 0.19M | -0.10M | - | - | - |
| Non currrent assets other | 3.25M | 3.25M | 3.25M | 3.25M | 0.00M |
| Non current assets total | 80.30M | 20.82M | 15.51M | 17.03M | 0.18M |
| Capital lease obligations | 7.89M | 9.92M | 11.64M | 13.48M | 0.00M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | -89.86M | -94.08M | -0.17M | -0.90M | -0.19M |
| Total cashflows from investing activities | -90.25M | -94.08M | -0.17M | - | - |
| Net borrowings | -0.53M | -0.41M | 3.58M | - | - |
| Total cash from financing activities | 216.79M | 88.78M | 103.79M | 0.19M | 150.86M |
| Net income | -99.96M | -98.33M | -66.39M | -59.28M | -50.62M |
| Change in cash | 27.98M | -86.45M | 44.13M | -55.27M | 106.49M |
| Begin period cash flow | 38.27M | 124.72M | 80.59M | 135.86M | 29.37M |
| End period cash flow | 66.25M | 38.27M | 124.72M | 80.59M | 135.86M |
| Total cash from operating activities | -98.56M | -81.15M | -59.50M | -54.56M | -44.18M |
| Issuance of capital stock | 234.02M | 88.71M | 100.25M | 0.02M | 151.06M |
| Depreciation | 0.38M | 2.00M | 1.84M | 1.15M | 0.01M |
| Other cashflows from investing activities | 0.02M | - | -0.05M | - | - |
| Sale purchase of stock | 80.00M | -0.02M | 0.00M | - | - |
| Other cashflows from financing activities | 216.79M | 0.49M | -0.04M | 0.35M | 150.86M |
| Capital expenditures | 0.40M | 0.48M | 0.17M | 0.90M | 0.19M |
| Change in working capital | -9.52M | 2.73M | 1.48M | 1.79M | 6.04M |
| Stock based compensation | 12.13M | 12.47M | 3.04M | 1.78M | 0.39M |
| Other non cash items | -1.60M | -0.02M | 0.53M | - | - |
| Free cash flow | -98.96M | -81.63M | -59.66M | -55.46M | -44.37M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| LXEO Lexeo Therapeutics, Inc. Common Stock |
-0.12 3.56% |
3.12 | - | 7.60 | 478.26 | 1.47 | 416.34 | -6.02 |
| NVO Novo Nordisk A/S |
-0.80 1.91% |
40.80 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-2.08 0.39% |
535.71 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
9.09 0.95% |
961.49 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
965.00 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
Lexeo Therapeutics, Inc., a clinical stage genetic medicine company, focuses on hereditary and acquired diseases with high unmet need in the United States. Its product pipeline comprises LX2006, an AAVrh10-based gene therapy candidate, which is in phase 1/2 clinical trial to treat friedreich ataxia cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate, which is in phase 1/2 to deliver a functional plakophilin-2 (PKP2) gene to cardiac muscle for the treatment of PKP2-ACM; and LX2021, a gene therapy candidate, which is in preclinical trial to deliver the coding sequence for the functional connexin 43, or Cx43, protein for a group of inherited cardiac muscle disorders associated with a high risk of sudden death, including arrhythmogenic cardiomyopathy (ACM) and certain forms of dilated cardiomyopathy. The company is also developing LX2022, a gene therapy candidate, which is in preclinical trial to deliver a functional TNNI3 gene to myocardial cells to treat a distinct form of hypertrophic cardiomyopathy. In addition, it is developing LX1001, LX1020, and LX1021, an AAVrh10-based gene therapy candidate, which has completed phase 1/2 clinical trial for the treatment of APOE4-associated Alzheimer's disease. The company has a license agreement with Cornell University to conduct the Phase 1/2 clinical trial of LX1001, as well as support the development of the LX1004 program; a research collaboration agreement with Cornell University to conduct preclinical research to develop the licensed technology; and third license agreement which obtained certain rights for FA cardiomyopathy, including rights to current and future clinical data from an ongoing Cornell University investigator-initiated Phase 1A trial of a gene therapy candidate. The company was founded in 2017 and is headquartered in New York, New York.
| Name | Title | Year Born |
|---|---|---|
| Mr. R. Nolan Townsend | CEO & Director | 1981 |
| Dr. Paul B. McCormac Ph.D. | Chief Technical Officer | 1970 |
| Ms. Jenny R. Robertson | Chief Business & Legal Officer | 1975 |
| Dr. Ronald G. Crystal M.D. | Co-Founder, Chief Scientific Advisor & Member of Scientific Advisory Board | NA |
| Dr. Eric Adler M.D. | Chief Medical Officer & Head of Research | 1974 |
| Dr. Jordan Shin M.D., Ph.D. | Senior Vice President of Clinical Development & Translational Science, Cardiology | NA |
| Dr. Jordan S. Dubow M.D. | Head of CNS Clinical Development | 1979 |
| Dr. Sandi See Tai M.D. | Chief Development Officer | 1971 |
| Mr. Ryan McHenry | VP & Corporate Controller | NA |
| Mr. R. Nolan Townsend M.B.A. | CEO & Director | 1981 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.